Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Glaxo Group Limited patent solves the following problem:

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 7528148 B2 deals with Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors.
The invention relates to a compound of formula (I) or a salt thereof: where: R1 is C1-4alkyl, C1-3fluoroalkyl or (CH2) 2OH; R2 is a hydrogen atom (H), methyl or C1fluoroalkyl; R3a is a hydrogen atom (H) or C1-3alkyl; P3 is optionally substituted branched C3-6alkyl, optionally substituted C3-8cycloalkyl, optionally substituted mono-unsaturated-C5-7cycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formulas (a), (bb) or (cc): B1 and B2 independently 1 or 2; and I was O, H, SO2, or NR4; and where Het sub-formula (i), (ii), (iii), (iv) or (b): The compounds of phosphodiesterase (PDE) inhibitor, in particular PDE4 inhibitor. Also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the making of a medication for the treatment and / or Branch Tomato with an inflammatory and / or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.